The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

The initial treatment for chronic myeloid leukemia in chronic phase (CP‐CML) represents a
complex process, which includes a prompt and precise diagnosis, the choice among three …

Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …

Ph+ chronic myeloid leukemia (CML) is a clonal myeloproliferative disease whose clinical
course is characterized by progression disease from the early chronic phase (CP) to the fatal …

Purpose of Review A large number of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and …

Abstract Treatment of chronic myeloid leukemia (CML) has been drastically changed by the
emergence of the ABL tyrosine kinase inhibitor (TKI), imatinib mesylate. However, resistance …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Over the last 2 decades, four major therapeutic approaches have drastically changed the
prognosis in chronic myelogenous leukemia (CML): 1) allogeneic stem cell transplant (SCT); …

Background Several tyrosine kinase inhibitors (TKIs) are available for treatment of patients
with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term …